Shares of MetLife (MET) closed at $38.09 Thursday, returning 22% year-to-date, following a 28% drop in 2011. The company paid an annual dividend of 74 cents in November, which was unchanged from a year earlier. The shares have a dividend yield of 1.94%.
The shares trade for 0.9 times tangible book value and 7.5 times the consensus 2012 EPS estimate of $5.09, making for the cheapest forward P/E among this group of five large-cap insurance companies. The consensus 2013 EPS estimate is $5.58.MetLife is in the midst of a transition from being considered a bank holding company, and consequent regulation by the Federal Reserve. The company agreed in November to sell "most of the depository business" of its MetLife Bank subsidiary to General Electric (GE) unit GE Capital. In January, MetLife announced it was exiting the forward residential mortgage business. MetLife continues to originate reverse mortgages and to service existing mortgage loans. The sale of the MetLife Bank depository business is expected to be completed during the second quarter, after which the company plans to deregister as a bank holding company. The Federal Reserve in October rejected a capital plan submitted by MetLife that included plans to increase the company's return of capital to investors, through dividend increases and share buybacks. The company is currently undergoing the annual round of Fed stress tests, with results expected to be publicly announced by the regulator on Friday. The company reported 2011 net income to common shareholders of $6.7 billion, or $6.29 a share, increasing from $2.7 billion, or $3.00 a share in 2010, with increases in premiums, policy fees and investment income growing total revenue by 34% to $70.3 billion. Bank of America Merrill Lynch analyst Edward Spehar rates MetLife a "Buy," with a price objective of $56, saying last Monday that "capital distribution will be a catalyst" for the shares this year, with a "substantial" dividend increase and share buybacks. Interested in more on MetLife? See TheStreet Ratings' report card for this stock. >>To see these stocks in action, visit the 5 Buy-Rated Insurance Stocks for Long-Term Investors portfolio on Stockpickr. -- Written by Philip van Doorn in Jupiter, Fla. To contact the writer, click here: Philip van Doorn. To follow the writer on Twitter, go to http://twitter.com/PhilipvanDoorn. To submit a news tip, send an email to: firstname.lastname@example.org.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV